This review investigated the use of coenzyme Q10 (CoQ10) supplementation to reduce the adverse effects of cancer treatments. It concluded that CoQ10 may offer some protection against cardiotoxicity or liver toxicity but, because of the poor study quality, these results may be unreliable and further research is needed. The review methods were appropriate and its conclusions are likely to be reliable.
The methodological quality and reporting of the included studies was poor. No study had a power calculation and the sample sizes were small (range: 19 to 88). Only one study was placebo-controlled and double-blind. All studies scored two points or less on the Jadad scale.
Three studies used ECG measurements to assess cardiotoxicity. One study reported statistically significant increases in QRS voltage and duration for the CoQ10 group compared with the control group. Another study reported statistically significant increases in the cardiothoracic ratio for the CoQ10 group. The third study did not report any between-group comparisons but found statistically significant increases in blood-pressure for the CoQ10 group; the ECG readings remained stable for more patients in this group than in the control group.
One study found no differences in hair loss or raised liver enzymes between the CoQ10 and control groups. One study reported that the percentage of left ventricular fractional shortening was statistically significantly lower for the CoQ10 group, but did not report any statistical results. One study reported that the administration of CoQ10 did not decrease the incidence of musculoskeletal toxicity, but resulted in a statistically significant reduction in its severity. No adverse effects of CoQ10 were reported in any of the studies.
Authors' conclusions
CoQ10 may provide some protection against the toxicity associated with cancer treatments, but this has not been tested by rigorous trials.
CRD commentary
This review had a clear research question and it specified study inclusion and exclusion criteria. The inclusion criteria specified eligible study designs and interventions but did not define specific outcomes, other than that the studies had to assess the clinical effects of CoQ10 supplementation. Several databases were searched and additional efforts to locate studies were made by searching references and departmental files and by contacting manufacturers. Studies were not restricted by language. Two reviewers independently extracted the data, which is good as this helps to minimise bias, although it was not clear whether two reviewers also screened the abstracts and performed the quality assessment. The studies were quality assessed using the Jadad scale which is used for assessing RCTs. However, the inclusion criteria did not specify that only RCTs were to be included, therefore the quality tool used may not have been the most appropriate for all of the included studies. Full details of the quality assessment were not provided for the individual studies, making it difficult for the reader to judge the quality of the studies for themselves.
The results of the studies were described narratively, which was appropriate given the clinical differences between them. Given the small number of studies found, and their poor quality, the authors' conclusions and recommendations
